Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
To observe the efficacy and safety of hydrochloride anlotinib combined with concurrent
radiochemotherapy for patients with FIGO stage IB3 and IIA2-IVA cervical cancer. Patient
characteristics, image and genetic information of tumor, microbial sample of tumor
microenvironment and biomarker in the blood sample will be collected and analysis by
multi-omics and bioinformatic technology. Aim to provide a new treatment module for cervical
cancer.